Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics

Background HER2 is overexpressed in 25–30% of breast cancer. Multiple domains targeting of a receptor can have synergistic/additive therapeutic effects. Methods Two domain-specific ADCs trastuzumab-PEG 6 -DM1 (domain IV) and pertuzumab-PEG 6 -DM1 (domain II) were developed, characterised and radiola...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2023-07, Vol.129 (1), p.153-162
Hauptverfasser:	Ketchemen, Jessica Pougoue, Babeker, Hanan, Tikum, Anjong Florence, Nambisan, Anand Krishnan, Njotu, Fabrice Ngoh, Nwangele, Emmanuel, Fonge, Humphrey
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059/602 631/67/2321 Animals Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Cytotoxicity Drug Resistance Epidemiology ErbB-2 protein Growth factors Mice Molecular Medicine Neoplasms - drug therapy Oncology Pharmacokinetics Precision Medicine Protein expression Receptor, ErbB-2 - metabolism Single photon emission computed tomography Tissue Distribution Trastuzumab Trastuzumab - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!